Lamb Lawrence 4
4 · IN8BIO, INC. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
IN8BIO EVP Lawrence Lamb Receives 72,000-Share Award
What Happened Lawrence Lamb, Executive Vice President and Chief Scientific Officer of IN8BIO (INAB), received a grant (derivative/option award) for 72,000 shares on February 4, 2026. The reported acquisition price is $0.00 (a stock option/award), so no cash was paid by the insider at grant. This was an award (code A), not an open-market purchase or sale.
Key Details
- Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (two days after the grant).
- Award: 72,000 shares subject to an option; reported price $0.00 (derivative).
- Vesting (per footnote): 25% vests on February 4, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
- Shares owned after transaction: not specified in the provided filing excerpt.
- No sale or immediate cashless exercise reported; this is a compensation/retention award rather than a market trade.
Context Option awards are common executive compensation and reflect future upside tied to continued service and company performance; they do not represent an immediate cash investment by the insider. Because this grant vests over time, its full economic value depends on future vesting and any future stock price movement. The filing appears timely (filed two days after the transaction).
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1]2026-02-04+72,000→ 72,000 totalExercise: $1.96Exp: 2036-02-04→ Common Stock (72,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.